Volatility across the digital asset market is reshaping investor priorities as sentiment weakens around several large-cap cryptocurrencies. Dogecoin and CardanoVolatility across the digital asset market is reshaping investor priorities as sentiment weakens around several large-cap cryptocurrencies. Dogecoin and Cardano

3 Best Cryptos to Invest In Now: Dogecoin (DOGE), Cardano (ADA), and This Under $0.04 DeFi Token

2025/12/22 21:50
4 min read

Volatility across the digital asset market is reshaping investor priorities as sentiment weakens around several large-cap cryptocurrencies. Dogecoin and Cardano are both navigating technically sensitive phases, prompting traders to reassess what crypto to buy now amid tightening liquidity and rising caution. 

At the same time, capital is increasingly rotating toward early-stage defi crypto projects with clearer growth runways. One such new crypto coin, Mutuum Finance, is drawing growing attention as its presale accelerates toward a critical inflection point, positioning it among the best cryptos to buy now for investors focused on 2025.

Dogecoin Price Under Pressure As Bearish Signals Build

Dogecoin is showing renewed weakness as investor confidence fades. The meme coin recently slipped nearly 3% to trade around $0.12, underperforming the broader market as macro uncertainty builds ahead of key CPI data. On-chain metrics reveal that large DOGE wallets holding between 100 million and 1 billion tokens have reduced their exposure by more than 1 billion DOGE since early December, reflecting declining conviction among whales.

Derivatives data reinforces this bearish outlook, with short positions now accounting for over 54% of DOGE futures activity. Technically, DOGE remains locked in a falling channel, trading well below its 50-day and 200-day moving averages, a structure that confirms longer-term downside pressure.

Analysts warn that if current levels fail to hold, Dogecoin could revisit the $0.074 support zone, where significant historical volume last changed hands. While short-term rebounds remain possible, DOGE’s setup highlights why many traders are reassessing which crypto to buy today for long-term positioning.

Cardano Nears Key Demand Zone As Ecosystem Liquidity Rotates

Cardano is approaching a decisive technical region as internal ecosystem activity begins to influence price behavior. ADA is compressing near the $0.30 demand zone, an area that previously preceded a major rally. Recent liquidity rotation tied to NIGHT token redemptions has redirected capital back into the Cardano ecosystem, reinforcing internal demand rather than speculative inflows.

More than 31 million NIGHT tokens are already circulating within the redemption cycle, with trading volumes surpassing 1.67 billion in 24 hours, signaling active capital deployment. This recycling mechanism has historically strengthened base-layer assets like ADA during corrective phases. From a structural standpoint, ADA remains within a descending channel, but price action suggests selling pressure is being absorbed rather than expanding. 

A confirmed rebound could target $0.48 and $0.60 initially, with a longer-term path toward $1 if demand remains intact. Even so, the current consolidation underscores why investors are diversifying into alternative opportunities when evaluating the best cryptocurrency to invest in today.

Mutuum Finance Emerges As An Under $0.04 DeFi Contender

While DOGE and ADA navigate uncertain technical landscapes, Mutuum Finance is gaining traction as a defi crypto still priced below $0.04. The project is currently in Presale Phase 6, which is now 99% filled, highlighting intense demand. Since presale began, Mutuum Finance has raised $19,500,000 and attracted 18550 holders, signaling broad-based participation at this stage. The current price in phase 6 is $0.035, already reflecting a 250% increase from the $0.01 phase one entry.

Phase 6 is selling out fast, meaning the window to secure MUTM at $0.035 is rapidly closing. Once Phase 7 opens, the token price will rise nearly 20% to $0.04, while the confirmed launch price is set at $0.06. Based on current pricing, early participants are positioning for a projected 410% gain after launch, reinforcing MUTM’s status as a best crypto to buy now among emerging projects.

Beyond pricing momentum, Mutuum’s fundamentals are a key driver of interest. A major update allows investors to purchase MUTM tokens using card payments with no purchase limits, significantly lowering entry barriers for global participants and accelerating adoption.

On the security front, Mutuum Finance has confirmed that an independent audit is in progress, with @HalbornSecurity reviewing its finalized lending and borrowing smart contracts under formal analysis. For investors weighing what crypto to invest in amid rising risk aversion, this focus on accessibility and security strengthens MUTM’s long-term appeal.

As Dogecoin faces bearish pressure and Cardano consolidates near critical support, Mutuum Finance is benefiting from early-stage momentum and presale scarcity. With Phase 6 nearly sold out and pricing set to rise imminently, MUTM is increasingly viewed as a best crypto to buy now for those seeking exposure before broader market recognition sets in.

For more information about Mutuum Finance (MUTM) visit the links below:

Website: https://mutuum.com/ 

Linktree: https://linktr.ee/mutuumfinance

The post 3 Best Cryptos to Invest In Now: Dogecoin (DOGE), Cardano (ADA), and This Under $0.04 DeFi Token appeared first on Blockonomi.

Market Opportunity
Best Wallet Logo
Best Wallet Price(BEST)
$0.001472
$0.001472$0.001472
+3.95%
USD
Best Wallet (BEST) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26